Humoral responses after inactivated COVID‐19 vaccination in individuals with and without prior SARS‐CoV‐2 infection: A prospective cohort study. Issue 12 (31st August 2022)

• Record Type: Journal Article
• Authors: Jia, Mengmeng; Wang, Xinming; Gong, Wensheng; Zhong, Jingchuan; Leng, Zhiwei; Ren, Lili; Feng, Luzhao; Guo, Li; Gao, Lidong; Liang, Xian; Chen, Enfu; Tang, Wenge; Huang, Qiangru; Zhang, Qiao; Jiang, Guangjiong; Zhao, Shanlu; Liu, Zhu; Feng, Yan; Qi, Li; Ma, Libing; Huang, Tingxuan; Yue, Yong; Wang, Ju; Jiang, Binshan; Xu, Liuhui; Wang, Jianwei; Yang, Weizhong; Wang, Chen
• Is Part Of: Journal of medical virology. Volume 94:Issue 12(2022)
• Page Start: 5746
• Page End: 5757
• Publication Date: 2022-08-31
• Subjects: humoral immunity -- inactivated COVID‐19 vaccine -- neutralizing antibody -- Omicron -- pan‐immunoglobulins; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28055
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: We evaluated and compared humoral immune responses after inactivated coronavirus disease 2019 (COVID‐19) vaccination among naïve individuals, asymptomatically infected individuals, and recovered patients with varying severity. In this multicenter, prospective cohort study, blood samples from 666 participants were collected before and after 2 doses of inactivated COVID‐19 vaccination. Among 392 severe acute respiratory syndrome coronavirus 2‐naïve individuals, the seroconversion rate increased significantly from 51.8% (median antispike protein pan‐immunoglobulins [S‐Igs] titer: 0.8 U/ml) after the first dose to 96% (median S‐Igs titer: 79.5 U/ml) after the second dose. Thirty‐two percent of naïve individuals had detectable neutralizing antibodies (NAbs) against the original strain but all of them lost neutralizing activity against the Omicron variant. In 274 individuals with natural infection, humoral immunity was significantly improved after a single vaccine dose, with median S‐Igs titers of 596.7, 1176, 1086.5, and 1828 U/ml for asymptomatic infections, mild cases, moderate cases, and severe/critical cases, respectively. NAb titers also improved significantly. However, the second dose did not substantially increase antibody levels. Although a booster dose is needed for those without infection, our findings indicate that recovered patients should receive only a single dose of the vaccine, regardless of the clinical severity, until there is sufficient evidence to confirm the benefits of a second dose.